Adaptimmune Therapeutics plc
ADAPNASDAQHealthcare
$0.05
$-0.00(-3.00%)
Market Cap$75157679
P/E Ratio—
52W High$0.86
52W Low$0.0202
Adaptimmune Therapeutics plc (ADAP) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADAP · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.07B) | ($0.11B) | ($0.17B) | ($0.16B) | ($0.13B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.02B | $0.02B | $0.01B |
| Change in Working Capital | ($0.04B) | ($0.02B) | ($0.00B) | $0.13B | $0.06B |
| Net Cash from Operations | ($0.07B) | ($0.14B) | ($0.14B) | $0.01B | ($0.05B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.03B) | ($0.01B) | ($0.00B) |
| Purchases of Investments | ($0.10B) | ($0.08B) | ($0.05B) | ($0.14B) | ($0.38B) |
| Sales of Investments | $0.04B | $0.21B | $0.17B | $0.22B | $0.11B |
| Net Cash from Investing | ($0.06B) | $0.18B | $0.09B | $0.08B | ($0.28B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.05B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.08B | $0.00B | $0.01B | $0.00B | $0.34B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.08B) | ($0.15B) | ($0.17B) | $0.00B | ($0.06B) |
| FCF Margin %(computed) | -42.65% | -241.80% | -631.76% | 31.68% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Adaptimmune Therapeutics plc data
About Adaptimmune Therapeutics plc (ADAP) Cash Flow Statement
Adaptimmune Therapeutics plc generated operating cash flow of ($0.07B) and free cash flow of ($0.08B) for 2024 — a FCF margin of -42.65%. Capital expenditure was ($0.00B).
Frequently asked questions
ADAP · 4 questionsAdaptimmune Therapeutics plc generated free cash flow of ($0.08B) for 2024, up 47.9% year-over-year.
ADAP free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10